Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review
Journal of Clinical Medicine · 26.09.2025 · 14 (19) · 6829
DOI: 10.3390/jcm14196829 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.09.2025. Verfasst von Hidenori Takahashi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Eosinophilic myocarditis (EM) is a rare, life-threatening inflammatory cardiomyopathy driven by eosinophil cytotoxicity and extracellular trap formation. Interleukin-5 (IL-5) inhibition may disrupt this pathogenic cascade. We reviewed contemporary evidence on IL-5 blockade in EM and contextualized it with an illustrative case.
Methods
We searched PubMed through May 2025 for reports of EM treated with mepolizumab or benralizumab. Inclusion criteria were consistent with prior cohorts: acute cardiac symptoms with biomarker elevation plus abnormalities on transthoracic echocardiography and/or cardiac magnetic resonance imaging (CMR), along with documented IL-5-targeted therapy. We extracted clinical, imaging, biopsy, treatment-timing, and outcome data and included one institutional case.
Results
Twenty-one episodes were analyzed (median age, 45 years; 10 men). Underlying conditions included eosinophilic granulomatosis with polyangiitis (10 cases; 48%), hypereosinophilic syndrome (5 cases; 24%), drug reaction with eosinophilia and systemic symptoms (DRESS, 3 cases; 14%), and eosinophilic asthma (3 cases; 14%). Treatments involved mepolizumab in 17 cases (81%) and benralizumab in 4 (19%); 4 patients received “early-start” therapy within 14 days of EM diagnosis. Among the 11 episodes with reported left ventricular ejection fraction (LVEF) at baseline and follow-up, the median baseline LVEF was 40% (range, 30–62), with 10 of 11 (91%)
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
- Department of Cardiovascular Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
- Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi Meguro-ku, Tokyo 153-8515, Japan.
- Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 1-1, Mitsuzawa-Nishimachi, Kanagawa-ku, Yokohama 221-0855, Kanagawa, Japan.
- Department of Diagnostic Pathology Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan.
ORCID-Profile: Hidenori Takahashi, Toru Awaya, Shinichiro Ota
Zitieren
APA
Takahashi, H., Awaya, T., Nagamatsu, H., Satake, Y., Hirose, R., Toba, N., Toyama-Kousaka, M., Ota, S., Morikawa, M., Tajiri, Y., Agemi, Y., Nakano, N., & Shinkai, M. (2025). Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review. Journal of Clinical Medicine, 14(19), 6829. https://doi.org/10.3390/jcm14196829
Vancouver
Takahashi H, Awaya T, Nagamatsu H, Satake Y, Hirose R, Toba N, et al. Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review. Journal of Clinical Medicine. 2025;14(19):6829. doi:10.3390/jcm14196829
BibTeX
@article{Takahashi2025,
author = {Takahashi, Hidenori and Awaya, Toru and Nagamatsu, Hiroki and Satake, Yugo and Hirose, Ryutaro and Toba, Naoya and Toyama-Kousaka, Mio and Ota, Shinichiro and Morikawa, Miwa and Tajiri, Yuta and Agemi, Yoko and Nakano, Natsuko and Shinkai, Masaharu},
title = {Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {19},
pages = {6829},
doi = {10.3390/jcm14196829}
}
EUVIMED